Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype

A Corrigendum to this article was published on 09 September 2014

This article has been updated


We demonstrate CRISPR-Cas9–mediated correction of a Fah mutation in hepatocytes in a mouse model of the human disease hereditary tyrosinemia. Delivery of components of the CRISPR-Cas9 system by hydrodynamic injection resulted in initial expression of the wild-type Fah protein in 1/250 liver cells. Expansion of Fah-positive hepatocytes rescued the body weight loss phenotype. Our study indicates that CRISPR-Cas9–mediated genome editing is possible in adult animals and has potential for correction of human genetic diseases.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Figure 1: Hydrodynamic injection of CRISPR components rescues lethal phenotype of Fah-deficient mice.
Figure 2: CRISPR-Cas9–mediated editing corrects Fah splicing mutation in the liver.

Accession codes



Change history

  • 31 March 2014

    In the version of this article initially published online, in the legend for Figure 1d, the scale bars are 100 μm and 20 μm, not “mm.” The error has been corrected for the print, PDF and HTML versions of this article.


  1. Cong, L. et al. Science 339, 819–823 (2013).

    Article  CAS  Google Scholar 

  2. Hsu, P.D. et al. Nat. Biotechnol. 31, 827–832 (2013).

    Article  CAS  Google Scholar 

  3. Mali, P. et al. Science 339, 823–826 (2013).

    Article  CAS  Google Scholar 

  4. Cho, S.W., Kim, S., Kim, J.M. & Kim, J.S. Nat. Biotechnol. 31, 230–232 (2013).

    Article  CAS  Google Scholar 

  5. Wu, Y. et al. Cell Stem Cell 13, 659–662 (2013).

    Article  CAS  Google Scholar 

  6. Schwank, G. et al. Cell Stem Cell 13, 653–658 (2013).

    Article  CAS  Google Scholar 

  7. Azuma, H. et al. Nat. Biotechnol. 25, 903–910 (2007).

    Article  CAS  Google Scholar 

  8. Paulk, N.K. et al. Hepatology 51, 1200–1208 (2010).

    Article  CAS  Google Scholar 

  9. Aponte, J.L. et al. Proc. Natl. Acad. Sci. USA 98, 641–645 (2001).

    Article  CAS  Google Scholar 

  10. Liu, F., Song, Y. & Liu, D. Gene Ther. 6, 1258–1266 (1999).

    Article  CAS  Google Scholar 

  11. Nielsen, R., Korneliussen, T., Albrechtsen, A., Li, Y. & Wang, J. PLoS ONE 7, e37558 (2012).

    Article  CAS  Google Scholar 

  12. Li, H. et al. Nature 475, 217–221 (2011).

    Article  CAS  Google Scholar 

  13. Fu, Y. et al. Nat. Biotechnol. 31, 822–826 (2013).

    Article  CAS  Google Scholar 

  14. Ran, F.A. et al. Cell 154, 1380–1389 (2013).

    Article  CAS  Google Scholar 

  15. Kanasty, R., Dorkin, J.R., Vegas, A. & Anderson, D. Nat. Mater. 12, 967–977 (2013).

    Article  CAS  Google Scholar 

Download references


We thank I. Zhuang and W. Cai for technical assistance, F. Zhang for sharing pX330 CRISPR vectors, and D. Crowley and K. Cormier for histology. This work was supported in part by grants 2-PO1-CA42063 to P.A.S. and T.J. and core grant P30-CA14051 from the National Cancer Institute. This work was supported in part by National Institutes of Health (NIH) Grant R01-CA133404 and the Marie-D. & Pierre Casimir-Lambert Fund to P.A.S. T.J. is a Howard Hughes Investigator, the David H. Koch Professor of Biology and a Daniel K. Ludwig Scholar. H.Y. and S.C. are supported by 5-U54-CA151884-04 NIH Centers for Cancer Nanotechnology Excellence and the Harvard-MIT Center of Cancer Nanotechnology Excellence. W.X. is supported by grant 1K99CA169512. S.C. is a Damon Runyon Fellow (DRG-2117-12). The authors acknowledge the service of the late Sean Collier to the MIT community. We thank the Swanson Biotechnology Center for technical support.

Author information

Authors and Affiliations



H.Y., W.X. and D.G.A. designed the study. H.Y., W.X., S.C., R.L.B. and E.B. performed experiments and analyzed data. M.G., V.K. and P.A.S. provided reagents and conceptual advice. H.Y., W.X., T.J. and D.G.A. wrote the manuscript.

Corresponding author

Correspondence to Daniel G Anderson.

Ethics declarations

Competing interests

D.G.A., H.Y., R.L.B., T.J. and W.X. have applied for patents on the subject matter of this paper.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1–8, Supplementary Discussion, Supplementary Methods and Supplementary Tables 1 and 2 (PDF 1521 kb)

Supplementary Table 3

Next-generation sequencing data for FAH2 treated mice. (XLSX 692 kb)

Supplementary Table 4

Next-generation sequencing data for off-target analysis of FAH2. (XLSX 47 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Yin, H., Xue, W., Chen, S. et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol 32, 551–553 (2014).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research